关注
TETSUHIRO HARIMOTO
TETSUHIRO HARIMOTO
在 g.harvard.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Zinc in depression: a meta-analysis
W Swardfager, N Herrmann, G Mazereeuw, K Goldberger, T Harimoto, ...
Biological psychiatry 74 (12), 872-878, 2013
2902013
A programmable encapsulation system improves delivery of therapeutic bacteria in mice
T Harimoto, J Hahn, YY Chen, J Im, J Zhang, N Hou, F Li, C Coker, K Gray, ...
Nature Biotechnology 40 (8), 1259-1269, 2022
1142022
Enhancing the tropism of bacteria via genetically programmed biosensors
T Chien, T Harimoto, B Kepecs, K Gray, C Coker, N Hou, K Pu, T Azad, ...
Nature biomedical engineering 6 (1), 94-104, 2022
822022
Active matter
S Tibbits
MIT press, 2017
602017
Respiratory‐related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005–2012) compared to other international registries
B Paes, I Mitchell, A Li, T Harimoto, KL Lanctôt
Journal of Immunology Research 2013 (1), 917068, 2013
512013
Predictors of readmission to a psychiatry inpatient unit
J Moss, A Li, J Tobin, IS Weinstein, T Harimoto, KL Lanctôt
Comprehensive Psychiatry 55 (3), 426-430, 2014
502014
Rapid screening of engineered microbial therapies in a 3D multicellular model
T Harimoto, ZS Singer, OS Velazquez, J Zhang, S Castro, TE Hinchliffe, ...
Proceedings of the National Academy of Sciences 116 (18), 9002-9007, 2019
402019
Risk factors for progression of Alzheimer disease in a Canadian population: the Canadian Outcomes Study in Dementia (COSID)
N Herrmann, T Harimoto, R Balshaw, KL Lanctôt, ...
The Canadian Journal of Psychiatry 60 (4), 189-199, 2015
362015
Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in Canada and Italy: an international, prospective cohort study
P Manzoni, B Paes, KL Lanctôt, A Dall’Agnola, I Mitchell, S Calabrese, ...
The Pediatric infectious disease journal 36 (1), 2-8, 2017
332017
Injectable therapeutic organoids using sacrificial hydrogels
NS Rossen, PN Anandakumaran, R Zur Nieden, K Lo, W Luo, C Park, ...
Iscience 23 (5), 2020
192020
Bacterial therapies at the interface of synthetic biology and nanomedicine
J Hahn, S Ding, J Im, T Harimoto, KW Leong, T Danino
Nature Reviews Bioengineering 2 (2), 120-135, 2024
152024
Engineering bacteria for cancer therapy
T Harimoto, T Danino
Emerging topics in life sciences 3 (5), 623-629, 2019
132019
A rapid screening platform to coculture bacteria within tumor spheroids
T Harimoto, D Deb, T Danino
Nature protocols 17 (10), 2216-2239, 2022
122022
Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer
D Deb, Y Wu, C Coker, T Harimoto, R Huang, T Danino
Scientific Reports 12 (1), 21551, 2022
32022
Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug
AR Decker-Farrell, SA Sastra, T Harimoto, MC Hasselluhn, CF Palermo, ...
bioRxiv, 2024.05. 02.592216, 2024
12024
Abstract B015: Toxin-producing bacterial therapy limits tumor growth in autochthonous mouse models of pancreatic ductal adenocarcinoma
AR Decker-Farrell, SA Sastra, T Harimoto, MC Hasselluhn, F Li, R Vincent, ...
Cancer Research 84 (2_Supplement), B015-B015, 2024
2024
Toxin-producing bacterial therapy limits tumor growth in autochthonous mouse models of pancreatic ductal adenocarcinoma
AR Decker-Farrell, SA Sastra, T Harimoto, MC Hasselluhn, F Li, R Vincent, ...
CANCER RESEARCH 84 (2), 2024
2024
411 Programming immunogenicity of bacterial cancer therapy with biosensor-driven encapsulation systems
J Hahn, T Harimoto, YY Chen, F Liguori, T Danino
Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023
2023
Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma.
AR Decker, T Harimoto, SA Sastra, T Danino, K Olive
CANCER RESEARCH 82 (22), 74-75, 2022
2022
Abstract B028: Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma
AR Decker, T Harimoto, SA Sastra, T Danino, K Olive
Cancer Research 82 (22_Supplement), B028-B028, 2022
2022
系统目前无法执行此操作,请稍后再试。
文章 1–20